Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QRFPR | Q96P65 | 2/20 | 0.42 |
| ▸ | NMT1 | P30419 | 5/20 | 0.42 |
| ▸ | NMT2 | O60551 | 4/20 | 0.42 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.42 |
| ▸ | NPY4R | P50391 | 6/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.40 |
| ▸ | NPY1R | P25929 | 5/20 | 0.40 |
| ▸ | NPY2R | P49146 | 3/20 | 0.40 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5606063 | 1.00 | QRFPR (0.42) | QRFPRNMT1NMT2SLC15A2NPY4R | |
| SCHEMBL31636034 | 1.00 | QRFPR (0.42) | QRFPRNMT1NMT2SLC15A2NPY4R | |
| SCHEMBL30027024 | 0.99 | NMT1 (0.44) | QRFPRNMT1NMT2SLC15A2NPY4R | |
| SCHEMBL29630364 | 0.96 | NMT1 (0.44) | QRFPRNMT1NMT2SLC15A2NPY4R | |
| SCHEMBL30711719 | 0.96 | NMT1 (0.44) | QRFPRNMT1NMT2SLC15A2NPY4R | |
| SCHEMBL29678881 | 0.95 | QRFPR (0.42) | QRFPRNMT1NMT2SLC15A2NPY4R | |
| SCHEMBL29777440 | 0.94 | GNPAT (0.44) | QRFPRNMT1NMT2SLC15A2NPY4R | |
| SCHEMBL3952951 | 0.93 | SLC15A2 (0.44) | SLC15A2NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29875467 | 0.93 | SLC15A2 (0.44) | SLC15A2NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29875780 | 0.93 | SLC15A2 (0.44) | SLC15A2NPY4RNPY5RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4608437-A2 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | Barinthus Biotherapeutics North America, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250242015-A1 | SELF-ASSEMBLING NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2025-07-31 | — | — | US | disclosed |
| US-12370255-B2 | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250127887-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-20240269269-A1 | Self-Assembling Nanoparticles | VACCITECH NORTH AMERICA, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| WO-2024092028-A2 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | VACCITECH NORTH AMERICA, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| CN-114634549-B | Collagen tripeptide product and preparation method and application thereof | 北京盛美诺生物技术有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-114634549-A | Collagen tripeptide product and preparation method and application thereof | 北京盛美诺生物技术有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-114099793-A | Immune cell capture device and methods of making and using same | 哈佛学院院长等 | 2022-03-01 | — | — | CN | disclosed |
| EP-1567179-A4 | IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF TUMOR CELL ADHESION, PAIN AND INFLAMMATION | OMEROS CORP (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1567179-A1 | IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF TUMOR CELL ADHESION, PAIN AND INFLAMMATION | Omeros Corporation (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004043479-A1 | IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF TUMOR CELL ADHESION, PAIN AND INFLAMMATION | OMEROS CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127887-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides | IAPP, BRCA1, ANXA11 | QRFPR 2223/4885NMT1 1290/4885NMT2 1717/4885 |
| US-20240269269-A1 | Self-Assembling Nanoparticles | UBE2B, CD4, UBE2G2 | QRFPR 1479/4885NMT1 443/4885NMT2 734/4885 |
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | IL2, IFNG, ICOS | QRFPR 2424/4885NMT1 2776/4885NMT2 3292/4885 |
| US-20250242015-A1 | SELF-ASSEMBLING NANOPARTICLES | UBE2B, CD4, HRH1 | QRFPR 1505/4885NMT1 451/4885NMT2 752/4885 |
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | VIP, HM13, SPPL2B | QRFPR 73/4885NMT1 849/4885NMT2 735/4885 |
| US-12370255-B2 | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response | MYD88, ICOS, CD4 | QRFPR 179/4885NMT1 1474/4885NMT2 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.